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Abstract To test the hypothesis that calcitonin gene-
related peptide (CGRP) modulates brain activity, we
investigated the effect of intravenous CGRP on brain
activity in response to a visual stimulus. In addition, we
examined if possible alteration in brain activity was
reversed by the anti-migraine drug sumatriptan. Eighteen
healthy volunteers were randomly allocated to receive
CGRP infusion (1.5 lg/min for 20 min) or placebo. In vivo
activity in the visual cortex was recorded before, during
and after infusion and after 6 mg subcutaneous sumatriptan
by functional magnetic resonance imaging (3 T). 77% of
the participants reported headache after CGRP. We found
no changes in brain activity after CGRP (P = 0.12) or after
placebo (P = 0.41). Sumatriptan did not affect brain
activity after CGRP (P = 0.71) or after placebo (P =
0.98). Systemic CGRP or sumatriptan has no direct effects
on the BOLD activity in visual cortex. This suggests that in
healthy volunteers both CGRP and sumatriptan may exert
their actions outside of the blood–brain barrier.
Keywords Calcitonin gene-related peptide (CGRP) 
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Introduction
Over the past 20 years, calcitonin gene-related peptide
(CGRP) has become a major focus of headache research [1].
CGRP has a wide distribution throughout the central and
peripheral nervous systems [2]. The headache-related pharma-
cological effects of CGRP were initially studied in the
peripheral nervous system, in particular, in the perivascular
space[3–5].Theﬁrstinvitrostudydemonstrated thatCGRP
is spontaneously released by cultured trigeminal ganglion
cells, and CGRP-containing nerve ﬁbers form a dense net-
work around cerebral vessels originating in the trigeminal
ganglia [6].Goadsby etal. reported the ﬁrst humanevidence
of CGRP release in the cranial circulation after thermoco-
agulation [7] and CGRP infusion in patients provokes
migraine attacks [8, 9]. Efﬁcacy of CGRP receptor antago-
nists [10, 11] in the acute treatment of migraine ﬁnally
proved the crucial role of CGRP in migraine and stimulated
the interest in its mechanisms of action. The most crucial
question is perhaps whether CGRP and its antagonists act in
the peripheral or central nervous system [12]. It has recently
been suggested that CGRP, in addition to its strong vasodi-
latory effect, also acts as an important and widespread neu-
romodulator in the brain [9, 12–14].
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DOI 10.1007/s10194-011-0415-4Using high resolution MRI angiography, we recently
reported that exogenous CGRP dilates extracranial arteries
and that this effect was blocked by anti-migraine drug
sumatriptan [14]. Whether exogenous CGRP also affects
neuronal activity in the trigeminal pain pathways in man is
unknown. Functional MRI (fMRI) using the blood oxy-
genation level-dependent (BOLD) response is the most
commonly employed method for in vivo studies of activity
in the human brain [15, 16]. The BOLD response is an
indirect method that measures neuronal activity by
recording associated changes in cerebral hemodynamics
[15–17]. The present study was primarily designed to test
the hypothesis that exogenous CGRP and sumatriptan
affect the BOLD response. We used a reversed checker-
board visual stimulation because it is a well validated,
reproducible stimulation modality known to produce a
large BOLD signal [18]. The effect of intravenous infusion
of CGRP and subcutaneous injection of sumatriptan on the
BOLD response was investigated in a placebo-controlled,
randomized, double-blind, crossover study of normal vol-
unteers. We hypothesized that CGRP infusion would alter
the BOLD response in the visual cortex and that the
selective anti-migraine drug, a 5-HT (types 5-HT1D and
5-HT1B) agonist sumatriptan would reverse CGRP
induced alterations in the BOLD response.
Methods
Subjects
We recruited 18 healthy volunteers [11 F and 7 M; mean
age 25 years (range 22–28) and mean weight 65 kg (range
53–77 kg]. Exclusion criteria were a history of serious
somatic disease, migraine or any other type of headache
(except episodic tension-type headache less than once a
month), daily intake of any medication except contracep-
tives; and contraindications for MRI scan.
All female participants used safe contraceptive methods.
Standard protocol approval, trail registration,
and patient consents
All participants gave informed consent to participate. The
Ethical Committee of Copenhagen (H-KA-20060083)
approved the study, which was conducted in accordance
with the Helsinki II Declaration of 1964, as revised in
Edinburgh in 2000.
Design and randomization
All participants were randomly allocated to receive infusion
of1.5 lg/min h-aCGRP(Calbiochem–Merck4Biosciences)
or placebo (isotonic saline) over 20 min and scanned on
two study days separated by at least 1 week. The CGRP
dose is known to induce headache in volunteers without
affecting the mean arterial blood pressure [19]. On both
experimental days, the participants received sumatriptan
(Imigran
 injection, Glaxo Wellcome Operations, Bernard
Castle, UK) 6 mg subcutaneous injection 42 min after start
of infusion. The ﬁrst part of the study investigated changes
in arterial circumference of middle meningeal and middle
cerebral arteries in response to CGRP and sumatriptan by
MR-angiography [14].
Experimental procedures
All participants reported headache free to the laboratory.
Coffee, tea, cocoa or other methylxanthine-containing
foods or beverages, and tobacco were not allowed for at
least 12 h before start of the study. Subjects were placed in
the supine position in MR scan room and a venous catheter
(Venﬂon
) was inserted into the left antecubital vein for
infusion. We collected blood samples to determine the
baseline hematocrit, potassium and sodium. The subjects
were monitored with ECG, end-tidal CO2 (capnograph,
Datex, Finland), blood oxygen saturation, blood pressure
and heart rate (Veris monitor, Medrad, USA).
MR imaging was performed on a 3.0 T Philips Achieva
Scanner (Philips Medical Systems, Best, The Netherlands)
using an eight-element phased-array receive head coil. We
ﬁrst obtained a reference anatomical whole-brain image
and then repeatedly measured the BOLD response after
visual stimulation with a reversing checkerboard. We
deﬁned time of drug administration as T0. The anatomical
image was recorded at -15 min, BOLD response at
-5 min and at 5, 15, 25, 40, 50, 60 and 75 min. Headache
intensity was recorded on a verbal rating scale (VRS) from
0 to 10 [0: no headache; 1: a very mild headache (including
a feeling of pressing or throbbing); 10: worst imaginable
headache] [20]. All variables were recorded at ﬁxed time
points throughout the study (Fig. 1a). Baseline was deﬁned
as before start of infusion (T-5min), the infusion phase
lasted from 0 to 40 min where recordings during the
infusion (0–20 min) and after the infusion were performed.
The period after sumatriptan injection was deﬁned as the
sumatriptan phase.
Data acquisition and imaging protocols
Anatomical Images
Anatomical images were acquired using a T1-weighted 3D
turbo ﬁeld echo sequence (170 sagittal slices 1 mm thick;
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123in-plane resolution 1 9 1 mm: repetition time 9.9 s; echo
time 4.6 ms; ﬂip angle 8o).
BOLD response
BOLD functional imaging utilized a gradient echo EPI
sequence (32 slices 4.0 mm thick; slice gap 0.1 mm; ﬁeld
of view 230 9 230 mm; in-plane acquired resolution
2.9 9 2.9 mm; repetition time 3.0 s; echo time 35 ms; ﬂip
angle 90; SENSE factor 2). Slices were oriented parallel
with the inferior border of corpus callosum covering the
whole brain. The ﬁrst four volumes of each run were dis-
carded to avoid saturation effects. We obtained 100 vol-
umes during each 5 min scan session.
To record the BOLD response, we applied visual stim-
ulation with a checkerboard. This is a well-established
modality that produces a rather large BOLD response in the
visual cortex. Accordingly, we choose the visual cortex
(V1, V2 and V3) as our region-of-interest (ROI). Visual
stimulation was presented with the Eloquence system
(Invivo, Orlando, Florida), using a pair of NNL goggles
(NordicNeuroLab, Bergen, Norway). A ﬁber-optic cable
connected the system to a control computer outside the
scanner room. The paradigm consisted of rest blocks,
where a uniform gray image was shown, alternating with
active blocks displaying a black and white checkerboard
reversing at 8 Hz. The block length was 1 min and two
activation periods were included during a scan session
which had a duration of 5 min. Subjects were asked to
ﬁxate on a central ﬁxation cross during the entire scan. The
onset of visual stimuli was triggered by the scan acquisi-
tion. Eye tracking (NordicNeuroLab, Bergen, Norway) was
used to monitor their level of ﬁxation.
Data analysis and statistics
BOLD data
Functional images were analyzed using FMRIB Software
Library (FSL) version 5.98, Oxford, UK (http://www.
fmrib.ox.ac.uk/fsl). FMRI Expert Analysis Tool (FEAT,
version 5.98) was used for pre-processing (ﬁrst level
analysis). Pre-processing steps included motion-correction,
brain extraction, and spatial (4 mm smoothing) and tem-
poral ﬁltering (high pass 200 s). A full quality assurance
Fig. 1 a The experimental paradigm. Baseline recordings were
performed at T-5min. All participants randomly received infusion of
CGRP (1.5 g/min) or placebo over 20 min. Injection of sumatriptan
was given at T42min. T1-weighted 3D anatomical images were
obtained at T-15min. BOLD-fMRI recordings were performed at
baseline, T5min, T15min, T25min, T35min, T45min, T55min and T65min. MR-
angiography’s of the middle meningeal artery and middle cerebral
artery were recorded at baseline, T30min and T60min. Headache scores,
blood pressure (BP), heart rate, end-tidal PCO2 and adverse events
(AEs) were recorded at baseline, T3min, T10min, T20min, T40min, T50min,
T70min and T75min. b Group analysis of the baseline scans (before drug
infusion) of 18 healthy subjects on CGRP study day. The images
show at strong activation in the visual cortex after visual stimula-
tion (arrows). Group analysis from the placebo day showed similar
results
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123(QA) was done prior to the statistical analysis. Scans with
severe distortions and/or excessive motion ([3 mm) were
excluded from further analysis. Those that passed QA were
included in the following statistical analysis. Statistical
results were co-registered ﬁrst to the subject’s own
T1-weighted 3D anatomical images and subsequently to a
standard Montreal Neurological Institute (MNI-152) atlas.
The 3D anatomical images were transformed to match the
dimensions of the functional scans using FSLSWAP and
brain extraction was performed using the FSL Brain
Extraction Tool (BET) (fractional intensity threshold: 0.6,
threshold gradient of -0.1, and robust brain center esti-
mation). For registration to the 3D anatomical images,
linear registration, full search and nine degrees of freedom
(DOF) were used, whereas 12 DOF was used for the sub-
sequent registration to the standard MNI-152 atlas. The
visual block stimulation paradigm convolved with a two
gamma hemodynamic response function served as a model
time course. Z (Gaussianised T/F) statistical images were
thresholded using clusters determined by Z[2.3 and a
(corrected) cluster signiﬁcance threshold of P = 0.05.
The BOLD response to visual stimulation was extracted
both as ROI expressed as COPE1 values (contrast of
parameter estimates) and voxel-wise. For the voxel-wise
analysis, the FEAT tool was used (FEAT FSL version
4.1.6, Oxford for Mac). For the ROI analysis, the visual
cortex (V1, V2 and V3) was identiﬁed based on the Juelich
Histological Atlas and normalized to the MNI structural
atlas (Feat query FSL, version 4.1.6, Oxford for Mac). The
extracted values were then transferred to SPSS 18.0 for
Mac (IBM SPSS, New York, USA) and baseline was
corrected before further statistical analysis.
ANOVA analysis of the effect and time and drug
All values are presented as mean ± SD and hemodynamic
peak responses as mean percentage from baseline [95%
conﬁdence interval (CI)] except vascular data (blood
pressure, heart rate, end-tidal PCO2, oxygen saturation),
which are presented as mean ± SEM.
The primary end-points were changes over time in rel-
ative BOLD response after infusion of CGRP or placebo,
difference in BOLD response between two experimental
days, difference in BOLD response before and after
sumatriptan administration and between experimental days.
We analyzed for changes over time for each experi-
mental day separately with analysis of variance (ANOVA)
with the ﬁxed factors subjects and time. To reduce mass
signiﬁcance, the following time points were selected for
analysis (T-5, T5, T15, T25 and T40). Baseline was deﬁned as
T-5. A second level analysis was performed to test CGRP
versus placebo using a two-way ANOVA with the ﬁxed
factors time and drug. The sumatriptan phase of the CGRP
day and the placebo day was analyzed in a similar way.
Analysis for changes over time was performed for each day
separately using ANOVA with subjects and time as ﬁxed
factors. The measured time points T50, T60 and T75 was
compared against the functional scan immediately pre-
ceding sumatriptan administration (T40). A second level
analysis was performed to compare the two study days.
We tested for period and carry-over effects for baseline
hemodynamic variables using independent t test. Five per-
cent (P\0.05) was accepted as the level of signiﬁcance.
Results
All participants completed the study on both study days.
Two subjects did not complete one scanning (5 min) each
due to temporary scanner breakdown. One scan from two
subjects had to be removed due to movement artefacts.
There was no carry-over or period effect for BOLD
response, blood pressure or heart rate (P[0.05). Baseline
blood samples showed normal hematocrit-, potassium- and
sodium levels. Blood pressure, heart rate, oxygen satura-
tion, end-tidal PCO2 did not change signiﬁcantly during the
experiment (P[0.05) (for details see supplementary
Table 1). All subjects showed a strong BOLD response to
visual stimulation. Group activation is shown in Fig. 1b.
Fourteen (77%) out of 18 participants reported CGRP
induced immediate headache during the observation period
of 0–42 min. Five participants reported headache on pla-
cebo day.
The effect of exogenous CGRP on the BOLD response
in the visual cortex
ANOVA did not show signiﬁcant changes over time in
activated voxels either on the CGRP day or on the placebo
day (Fig. 2a, b). ANOVA of the COPE recordings in the
visual cortex revealed no statistical changes after CGRP
(P = 0.12) or placebo infusion (P = 0.41). We found no
difference with regard to activated voxels or recordings of
COPE1 values between the two experimental days
(P = 0.357) (Fig. 2c).
The effect of sumatriptan on the BOLD response
in the visual cortex
On the CGRP day, one-way voxel-wise ANOVA after
sumatriptan administration showed scattered activation at
T45min. The activated voxels were located primarily in the
cerebellum and in the white matter of the corpus callosum.
There were no activated voxels in the visual cortex that was
the predeﬁned ROI or in other areas directly related to
visual stimulation. The remaining recordings did not show
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123signiﬁcantly activated voxels. On the placebo day, one-way
voxel-wise ANOVA revealed no signiﬁcantly activated
voxels (Fig. 2a, b). One-way ANOVA of the COPE1
recording values after sumatriptan administration revealed
no statistical changes either on the CGRP day (P = 0.71)
or on the placebo day (P = 0.98). We found no difference
Fig. 2 a One-way voxel-wise
ANOVA results from the
measured time points at the
CGRP day (left side) and
placebo day (right side).
ANOVA showed no statistical
changes over time in activated
voxels after CGRP and placebo
infusion except some scattered
activation after sumatriptan
injection on CGRP day. The
activated voxels were located
primarily in the cerebellum and
in the white matter of the corpus
callosum (arrows). There were
no activated voxels in the
predeﬁned visual region-of-
interest. b Second level analysis
revealed no statistical difference
between two experimental days.
The pictures show the mean
subtracted values between
placebo day and the CGRP day.
c Baseline corrected contrast of
parameter estimate (COPE1)
results from the visual region-
of-interest. ANOVA revealed
no statistical changes after
CGRP (P = 0.12) or placebo
infusion (P = 0.41). We found
no statistical difference between
two experimental days
(P = 0.357). ANOVA revealed
no statistical changes after
injection of sumatriptan either
on the CGRP (P = 0.71) or on
the placebo days (P = 0.98).
We found no statistical after
sumatriptan between two
experimental days (P = 0.49)
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123in activated voxels or recordings of COPE1 values between
two experimental days (P = 0.49) (Fig. 2c).
Discussion
The present study investigates for the ﬁrst time the effect of
intravenous CGRP and sumatriptan on brain activity using
fMRI. Systemic administration of CGRP and sumatriptan
caused no changes in neuronal activity of the visual cortex.
Before discussing the main results, we shall brieﬂy clarify
some important issues regarding methods applied in the
present study. When interpreting pharmacological fMRI
data, it is important to keep in mind that changes in brain
hemodynamics such as CBF, CBV and CMRO2 can alter
the measured BOLD signal [21]. The BOLD signal is an
indirect way of measuring brain activation. During brain
activation, the increased supply of oxyhemoglobin results
in a relative decrease in deoxyhemoglobin. While deoxy-
hemoglobin is paramagnetic and oxyhemoglobin is dia-
magnetic, brain activation results in an increased MR
signal as detected by appropriate MR techniques. CGRP is
a very potent vasodilator and may theoretically affect the
BOLD response. Therefore, as a ﬁrst step to quantifying
altered brain activity we investigated the effect of CGRP
on the BOLD response in healthy volunteers. Experiments
in healthy volunteers are usually a precondition for later
studies in pathological conditions. We furthermore con-
sidered it as a necessary step to study the BOLD response
in the visual cortex for the following reasons: (1) Visual
stimulation produces a large BOLD signal in the visual
cortex and, therefore, possible effects of CGRP on the
BOLD response would be easy to quantify; (2) Before
investigating possible speciﬁc effects of CGRP in the tri-
geminal pain pathways, it is important to determine if
possible modulation of the BOLD signal is due to speciﬁc
changes in these pathways or accounted to a general effect
of CGRP on the BOLD signal. (3) The visual cortex is
considered as an important compartment in migraine
research [22] and before investigating possible effect of
exogenous CGRP on excitability of visual cortex during
headache in migraineurs, it is important to determine its
effect in healthy volunteers.
Cerebral effect of CGRP
The most important question raised by CGRP provocation
experiments is whether intravenous infusion of CGRP
induces headache inside or outside of the blood–brain
barrier (BBB). The BBB is formed by the tight junctions
between endothelial cells in cerebral vessels and the vas-
cular smooth muscle cells are placed inside the BBB.
Studies of cerebral arterial diameter or cerebral blood
ﬂow may, therefore, elucidate mechanisms underlying the
effects of exogenous CGRP on the brain, when given sys-
temically. Experimental studies in healthy volunteers [23]
and migraine sufferers [24] reported no effect of intrave-
nous infusion of CGRP on global or regional CBF. In vitro
studies have shown that intraluminal CGRP did not dilate
cerebral arteries but extraluminal application of CGRP did
[13]. Together these studies indicate that exogenous CGRP
does not cross the BBB in cerebral arteries.
CGRP is found in many regions of the CNS including
visual cortex [12]. Interestingly, CGRP receptors are not
detected in central glial cells or second order neurons [25].
It has been reported that CGRP facilitates glutamatergic
neurotransmission in the dorsal horn of the spinal cord [26].
Furthermore, CGRP may modulate central sensitization by
increasing the discharge frequency of wide dynamic range
neurons in the spinal cord, thus modulating nociceptive
transmission [27]. Interestingly, two studies have found that
CGRP release is anti-nociceptive [28, 29].
Extracerebral effect of CGRP
CGRP is one of the most powerful vasodilators [30] and its
receptor components are found in the smooth muscle cells
of cranial arteries [31, 32]. In arteries without a BBB such
as the MMA, exogenous CGRP reaches the smooth muscle
cells and dilates the artery [32]. Petersen et al. [13] dem-
onstrated that the extracerebral artery MMA relaxed after
intraluminal administration of CGRP. In vitro studies of
human [33, 34] and rat [35] MMA reported similar results.
Previous human experiments showed 30% dilatation of the
superﬁcial temporal artery after CGRP infusion [8]. In the
present study, we recorded BOLD-fMRI data and MRA
data simultaneously. Angiography results of middle men-
ingeal artery (MMA) and middle cerebral artery (MCA)
have been previously presented [14]. We found that CGRP
infusion induced a dilatation of MMA of 9.2%, but failed
to induce diameter changes in the MCA or to alter baseline
BOLD signal (see Fig. 3). Thus, CGRP acts outside of the
BBB.
Effect of sumatriptan on brain activity
The mechanism of anti-migraine action of triptans remains
a matter of intense research and debate [36]. Sumatriptan
(HT1B/1D receptor agonist) was originally developed as a
selective cranial vasoconstrictor [37]. Electrophysiological
studies on animals reported peripheral [36, 38] and central
sites of action in the trigeminal pain pathway [39]. Sakai
et al. [40] reported that the increased brain 5-HT synthetic
rate during a migraine attack was reversed by sumatriptan.
It is unclear, however, whether this was due to a direct or
indirect effect of sumatriptan on the brain. In the present
164 J Headache Pain (2012) 13:159–166
123study, sumatriptan did not affect visual cortex activity or
diameter of the MCA. However, sumatriptan reversed
CGRP-induced dilatation of the MMA in healthy volun-
teers [14] and in migraine patients during CGRP-induced
migraine [9]. These data suggest that sumatriptan does not
cross the BBB but acts outside of the BBB possibly by
contracting the MMA.
Conclusion
Systemic administration of CGRP or sumatriptan has no
direct effects on the BOLD signal in healthy volunteers.
Given systemically, both migraine provoking peptide
CGRP and anti-migraine drug sumatriptan do not modulate
BOLD responses in the visual cortex.
Clinical trial registration The Ethical Committee of
Copenhagen (H-KA-20060083) approved the study.
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